Short hairpin RNAs targeting M and N genes reduce replication of porcine deltacoronavirus in ST cells

Gu, Wenyuan; Li, Yan; Liu, Bao-jing; Wang, Jing; Yuan, Guangfu; Chen, Shaojie; Zuo, Yuanmei; Fan, Juan

doi:10.1007/s11262-019-01701-y

Cited by 9 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, Dicer-substrate siRNAs provided equivalent or better potency than canonical siRNAs for FIPV. In the context of porcine deltacoronavirus (PDCoV), two short hairpin RNA (shRNA)-expressing plasmids targeting the M (pGenesil-M) and N (pGenesil-N) genes of PDCoV were evaluated in swine testicular (ST) cells [126]. Challenges with the PDCoV HB-BD strain provided highly specific and efficient protection of ST cells.…”

Section: Gene Silencingmentioning

confidence: 99%

Coronavirus Pandemic—Therapy and Vaccines

Lundström¹

2020

Biomedicines

View full text Add to dashboard Cite

The current coronavirus COVID-19 pandemic, which originated in Wuhan, China, has raised significant social, psychological and economic concerns in addition to direct medical issues. The rapid spread of severe acute respiratory syndrome-coronavirus (SARS-CoV)-2 to almost every country on the globe and the failure to contain the infections have contributed to fear and panic worldwide. The lack of available and efficient antiviral drugs or vaccines has further worsened the situation. For these reasons, it cannot be overstated that an accelerated effort for the development of novel drugs and vaccines is needed. In this context, novel approaches in both gene therapy and vaccine development are essential. Previous experience from SARS-and MERS-coronavirus vaccine and drug development projects have targeted glycoprotein epitopes, monoclonal antibodies, angiotensin receptor blockers and gene silencing technologies, which may be useful for COVID-19 too. Moreover, existing antivirals used for other types of viral infections have been considered as urgent action is necessary. This review aims at providing a background of coronavirus genetics and biology, examples of therapeutic and vaccine strategies taken and potential innovative novel approaches in progress.

show abstract

Section: Gene Silencingmentioning

confidence: 99%

Coronavirus Pandemic—Therapy and Vaccines

Lundström¹

2020

Biomedicines

View full text Add to dashboard Cite

show abstract

“…In the context of MERS-CoV, four miRNAs and five siRNAs targeting the ORF1ab region have been rationally designed by computational calculations for gene silencing [ 86 ]. RNAi has further been applied for other coronaviruses such as porcine deltacoronavirus (PDCoV), where two plasmid-based shRNAs targeting the PDCoV M and N genes were evaluated in swine testicular (ST) cells [ 87 ]. Treatment of ST cells with M and N shRNAs reduced the PDCoV titers by 13.2- and 32.4-fold, respectively, and decreased the viral RNA by 45.8% and 56.1%, respectively.…”

Section: Rnai-based Antiviral Therapy Using Non-viral Deliverymentioning

confidence: 99%

Viral Vectors Applied for RNAi-Based Antiviral Therapy

Lundström¹

2020

Viruses

View full text Add to dashboard Cite

RNA interference (RNAi) provides the means for alternative antiviral therapy. Delivery of RNAi in the form of short interfering RNA (siRNA), short hairpin RNA (shRNA) and micro-RNA (miRNA) have demonstrated efficacy in gene silencing for therapeutic applications against viral diseases. Bioinformatics has played an important role in the design of efficient RNAi sequences targeting various pathogenic viruses. However, stability and delivery of RNAi molecules have presented serious obstacles for reaching therapeutic efficacy. For this reason, RNA modifications and formulation of nanoparticles have proven useful for non-viral delivery of RNAi molecules. On the other hand, utilization of viral vectors and particularly self-replicating RNA virus vectors can be considered as an attractive alternative. In this review, examples of antiviral therapy applying RNAi-based approaches in various animal models will be described. Due to the current coronavirus pandemic, a special emphasis will be dedicated to targeting Coronavirus Disease-19 (COVID-19).

show abstract

“…Combined siRNA therapy was shown to prevent escape of siRNA-resistant FCoV mutants in vitro [ 229 ]. siRNAs restricted viral protein expression and inhibited the replication of PEDV, PDCoV, PHEV, and SADS-CoV in vitro [ 230 , 231 , 232 ]. siRNA expression inhibited virus replication, lowered inflammation, significantly decreased mortality, and improved weight gain in poultry experimentally infected with IBV [ 233 ].…”

Section: Therapeutics Against Sars-cov-2 and The Animal Coronavirumentioning

confidence: 99%

Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses

Ghosh

Malik

2020

Microorganisms

View full text Add to dashboard Cite

The COVID-19 pandemic, caused by a novel zoonotic coronavirus (CoV), SARS-CoV-2, has infected 46,182 million people, resulting in 1,197,026 deaths (as of 1 November 2020), with devastating and far-reaching impacts on economies and societies worldwide. The complex origin, extended human-to-human transmission, pathogenesis, host immune responses, and various clinical presentations of SARS-CoV-2 have presented serious challenges in understanding and combating the pandemic situation. Human CoVs gained attention only after the SARS-CoV outbreak of 2002–2003. On the other hand, animal CoVs have been studied extensively for many decades, providing a plethora of important information on their genetic diversity, transmission, tissue tropism and pathology, host immunity, and therapeutic and prophylactic strategies, some of which have striking resemblance to those seen with SARS-CoV-2. Moreover, the evolution of human CoVs, including SARS-CoV-2, is intermingled with those of animal CoVs. In this comprehensive review, attempts have been made to compare the current knowledge on evolution, transmission, pathogenesis, immunopathology, therapeutics, and prophylaxis of SARS-CoV-2 with those of various animal CoVs. Information on animal CoVs might enhance our understanding of SARS-CoV-2, and accordingly, benefit the development of effective control and prevention strategies against COVID-19.

show abstract

Short hairpin RNAs targeting M and N genes reduce replication of porcine deltacoronavirus in ST cells

Cited by 9 publications

References 25 publications

Coronavirus Pandemic—Therapy and Vaccines

Coronavirus Pandemic—Therapy and Vaccines

Viral Vectors Applied for RNAi-Based Antiviral Therapy

Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses

Contact Info

Product

Resources

About